Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:01 PM
Ignite Modification Date:
2025-12-24 @ 10:01 PM
NCT ID:
NCT00726232
Eligibility Criteria:
Inclusion Criteria:
* Confirmed diagnosis of polycythemia vera or essential thrombocythemia as determined by treating physician
* Disease refractory to hydroxyurea or for whom treatment with hydroxyurea is contraindicated or have refused further treatment with hydroxyurea due to side effects.
* Patient meets baseline clinical lab parameters
Exclusion Criteria:
* Treatment with interferon alpha or anagrelide within 7 days and hydroxyurea within 1 day of starting INCB018424.
* Patients diagnosed with another malignancy unless the malignancy was cervical intraepithelial neoplasia or basal or squamous cell skin cancer and the patient has been disease free for \> 3 years
* Patients receiving therapy with intermediate or high dose steroids greater than the equivalent of 10 mg prednisone per day
* Clinically significant cardiac disease (New York Heart Association (NYHA) Class III or IV)
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00726232
Study Brief:
Protocol Section:
NCT00726232